Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NT 201 versus Vistabel for glabellar frown lines
2008-002713-40Phase 3Completed
- Sponsor
- Merz
- Start
- Aug 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of botulinum toxin type A in glabellar furrowing (2 arms), sponsored by Merz. Primary endpoint: Primary efficacy endpoint. Started Aug 2008; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
glabellar furrowing
Beyond the preview
Go deeper on 2008-002713-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002713-40.